. Although the experience with other RT inhibitors, such as 2/,3'-dideoxy inosine (ddl), is much more limited, preliminary evidence, as well as theoretical considerations, suggest that also these drugs may show the same phenomenology (Yarchoan et aI., 1990; St Clair et al., 1991) .
At least in theory these problems could be reduced by combined therapy with more than one drug. The 'rationale' for this strategy includes: (1) the dosage of each 'toxic' drug could be reduced ifthe drugs act synergistically; (2)it is likely that the combination of two or more drugs could prevent or delay the emergence of drug-resistant strains; and (3) if two drugs recognize different cellular targets, their combination may lead to a higher therapeutic activity.
In this view in vitro models aimed to study the interaction among different drugs and capable of mimicking their effects in vivo in terms of reduction of viral replication and of abolishment or delay or drug resistance are desirable.
This paper addresses the potential usefulness of the combination between AZT and ddl. It is known that neither AZT nor ddl have intrinsic activity against HIV, since they must be modified by cellular enzymes to carry out the antiviral activity. The interaction of these nucleoside analogues with cellular enzymes leads to the development of unwanted side effects. Additionally, strains resistant to either AZT or ddl have been isolated from patients during treatment with each drug (Larder et aI., 1989; St Clair et al., 1991; Gao et al., 1992a) . It is of interest to study whether the combination between AZT and ddl would alleviate these problems by prospectively consenting a dose reduction still maintaining the same antiviral effect and/or reducing the emergence of drug resistance. Both of the aforementioned aspects have been explored. Namely, we explored whether the two drugs act synergistically against HIV-1 replication. Additionally, by growing the virus in the presence of the drug and measuring the level of sensitivity of the progeny virus by back-titration of the viral yield we address the question of whether the combination of these two drugs could prevent or delay the appearance of AZT-resistant mutants.
The effect of combined treatment with AZT and ddl in C8166 or PBMC cultures infected with HIV-1 (HTLV-IIIB strain) has been studied using the following experimental G. AntonellV F. Dianzani The reverse transcriptase (Rl) inhibitor 3'-azido-3/deoxythymidine (AZl) has been widely used for therapy of AIDS and asymptomatic patients with less than 500 CD4+ T-Iymphocytes per mm", In both cohorts of patients the use of this drug has been remarkably successful by reducing viraemia, preventing the incidence of opportunistic infections, improving the quality of life and significantly prolonging survival of AIDS patients (Fischl et al., 1987 (Fischl et al., , 1990 Volberding et al., 1990) . Unfortunately, these favourable results are only transient and often long-term treatment leads to serious toxicity and/or to selection of drug-resistant HIV strains (Richman et al., 1987; Dournon Summary Both 3'-azido-3'-deoxythymidine (AZT) and 2',3'dideoxynosine (ddl) strongly inhib.ft the replication of human immunodeficiency virus tY~e 1 (HIV-1). Here, it is shown that combination of AZT and ddl at concentrations that are readily achievable in vivo synergistically inhibit HIV-1 replication in C8166 cells and peripheral blood mononuclear cells. The synergism is significant even when the effect of AZT and ddl alone was negligible.
Our findings show that AZT -resistance is less likely to occur when a combination of AZT and ddl is used. Particularly, generation of AZT -resistant strains by in vitro selection is prevented, or delayed, by the combination of AZT plus ddl.
Taken together these observations provide a rationale for combination of AZT and ddl in the therapy of AIDS patients. r I i 52 G. Antonelli et al.
procedure: suboptimal doses of each compound chosen below their 10 50 values, previously established as 3 nM for AZT (Sigma Chemical Company, St Louis, MO) and 1000nM for ddl (kindly provided by Bristol Myers Squibb) were added to C8166 infected with HIV-1 at a MOl of 0.01. After 72 h incubation, the cells were subjected to three cycles of freeze-thawing, cell debris were removed and the supernatants were titrated as previously described (Oianzani et al., 1988 (Oianzani et al., , 1989 Antonelli et al., 1992) .
Cytotoxicity induced by both drugs added to C8166 cultures was determined by assays employing the conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-Iium bromide (MTI; Sigma Chemical Company) to MTI formazan as a measure of cell integrity (Oenizot and Lang, 1986) . No toxicity was observed at drug concentrations exceeding 100-fold those used in the experiments.
The results of the experiments carried out in C8166 cells are shown in Table 1 . The values represent the average of three independent experiments. The method of Chou and Talalay for the calculation of combination index (CI) was followed (Chou and Talalay, 1984; Hartshorn et al., 1987) . It can be seen that at each condition the reduction of virus yield by the combined drugs is greater than expected for merely additive effects, with CI showing a clear synergistic interaction (CI < 1.0). Synergism is stronger with the lower doses, but it is still significant with drug concentrations approaching the 10 50 values, while the best antiviral effect is seen at higher dose combinations.
Basically the same results have been obtained using PBMC cultures derived from healthy donors, shown in Table 2 . The experimental plan reflects that used for the Iymphoblastoid cell cultures, except here the reduction of virus yield has been measured as production of viral antigens rather than as infectious virus. Additionally, the ratio ddl to AZT of 20:1 (instead of 250:1 used in C8166 cells) has been used, due to the lower sensitivity of PBMC to AZT as compared to C8166 cells. The Cis show at each combination tested a clear, albeit less strong, synergistic interaction. It should be mentioned that in both PBMC and C8166 cells a lower, but still significant, synergistic effect can be observed also at different drug molar ratio.
Taken together these findings strongly suggest that a combination therapy with AZT and ddl may be more effective in inhibiting HIV-1 replication as compared to monotherapy.
Further experiments have been performed to explore the possibility that such a combination could prevent the selection of drug-resistant strains of HIV-1.
It is known that emergence of AZT-resistant strains of HIV can be obtained in vitro by serially culturing HIV-1 in the presence of inhibitory concentrations of AZT Oianzani et aI., 1992) . Thus, in an attempt to establish whether the concomitant treatment with ddl would prevent or modify the occurrence of AZT-resis- tance, cultures of C8166 cells were infected with HIV-1 (HTLV-IIIB strain) at initial MOl of 0.01 in the presence of AZT 7 nM or AZT 7 nM plus ddl 2000 nM, l.e, approximately two-fold the 10 50 values. When virus-induced syncytia became evident, the supernatants were titrated and used to infect at approximately the same MOl fresh cultures of C8166 supplemented with AZT or AZT plus ddl. At each passage both drugs were progressively doubled. At every passage aliquots of the virus yields were collected and stored at -80 aC for subsequent testing of sensitivity to AZT. This was carried out after the seventh passage. To this purpose 6 x 10 5 cells were incubated with HIV-1, HIV-AZT (l.e, derived fromAZT-treated cultures) or HIV-AZT plus ddl (Le. derived from AZT plus ddl treated cultures) at MOl of 0.01. At the same time, dilution of AZT were added to a 96-well microtitre plate. One hour later, the cells were washed three-times, resuspended in 2 ml of medium and distributed into the wells containing the drug. After 72 h of incubation at 37"C, the cells were subjected to three cycles of freeze-thawing, cell debris were removed and the supernatants were titrated as described before (Oianzani etal., 1988 (Oianzani etal., , 1989 . The results of this experiment are shown in Table 3 . It can be seen that while the virus passed in the presence of AZT alone gradually acquires a significant level of resistance to this drug, that passed in the presence of AZT plus ddl undergoes not statistically si9f;lificant changes of its sensitivity to AZT, with an ID 50 sUb~~antiaIlY stable and an IDgo increased less than two-fold.JAlthough the degree of AZT resistance acquired after this limited number of passages is modest, as already reported by others (Larder et aI., 1991; Dianzaniet a/., 1992) , it can be concluded that the concomitant treatments with ddl substantially prevents selection of AZT-resistant mutants.
Taken together these findings suggest that the combination therapy of AZT and ddl could result in a higher therapeutic efficacy as a consequence of their synergistic effect and of the capability to inhibit or delay the appearance of drug-resistant variants of HIV-1.
These findings are not entirely new if one considers that AZT plus ddl synergy have been preliminarly reported both in vitro and in clinical trials (Johnson et el., 1990; Merigan, 1991; Dornsife eta/., 1991; Cox eta/., 1992;  R. Yarchoan et a/., National Cancer Institute, Bethesda, MD, personal communication). Nevertheless, this study offers the opportunity to monitor more closely such a phenomenon and provides this opportunity for future molecular studies on its mechanism. Although their practical implications are clear, both findings require theoretical interpretations concerning the underlying mechanisms that are not obvious.
First, synergism is usually seen with drugs having different mechanisms of antiviral action (Hartshorn et sl., 1987; Johnson et a/., 1990; O'Marro et a/., 1992) while here a favourable interaction occurs between drugs, such as AZT and ddl which, although phosphorylated by different pathways, have a similar mechanism of action. However this is not wholly unexpected if one considers that several differences have been noted in the anti-HIV activity of different nucleoside analogues, i.e. differences in the rate Drug combination ofAZT and ddt 53 of phosphorylation, in the affinity for RTenzyme and in the ability to compete with the cellular nucleotides (DeClercq, 1989) .Additionally, since AZT is a dTIP analogue and ddl is a dATP analogue, they may prevent the incorporation of the natural substrates by acting at different sites in the RT enzyme.
Second, our results indicate that the synergism between AZT and ddl is highly significant at dosages below their individual ID 50 values while the CI values approach 1 concomitantly with the increaseofthe dosage. This finding may be explained considering that at high concentration both drugs practically suppress the viral replication making difficult the calculation of the CI values.
As far as the emergence of drug-resistance is concerned, the prevention of appearance of AZT-resistant HIV-strains by combining AZT and ddl could reflect the synergistic effect of the combined therapy. This is consistant with the hypothesis that the synergistic effect of AZT and ddl diminish or abrogate the replicative events of HIV-1, making difficult the emergence of AZT-resistant strains and suggesting that the observed effect may reflect a delay and not an actual block of the appearance of AZT-resistance. However, one should consider that the experimental procedure has been designed to overcome the problem of synergistic antiviral action of AZT plus ddl. In fact, although the c.p.e. and the viral yield is significantly delayed in AZT plus ddl-treated cultures compared to AZT-treated cultures, the virus was always collected from both cultures and used to infect fresh cell cultures at the same Mal. This means that at each passage the viral preparation produced by AZT plus ddl-treated cultures contains fewer AZT-resistant variants compared to AZTtreated cultures.
It is also possible that the addition of ddl in the culture inhibit the replication of AZT-resistant strains selected during the propagation of the virus in culture. This would imply that ddl can prevent the production of viral progeny from cells newly infected with AZT-resistant mutants. Indeed, drug combination between AZT and ddl has been shown to inhibit replication of AZT-resistant strains (Gao et si., 1992b; Johnson et sl., 1991) and the mutational basis for increased resistance to AZT or ddl have been shown to be different (St Clair et el., 1991; Gao et aI., 1992a) . However, no definite conclusions can be drawn since apparently this hypothesis is in contrast with the recently published data on the partial cross-resistance between AZT and ddl (Rooke et el., 1989; Dianzani et sl., 1992) .
Another possibility is that the lack of AZT resistance arising in culture treated with AZT plus ddl is due to combined mutations leading to profound modifications of RT enzyme which are not compatible with survival of AZT-resistant viruses. Indeed, it has been proposed recently (St Clair et aI., 1991) that ddHnduced mutation in the mutated AZT-resistant HIV-1 strains generates an AZT-sensitive virus once again.
In conclusion, although some questions remain open, our observations indicate, within the limitations implied in an in vitro experimental model, that a combination therapy with AZT and ddl may be clinically useful.
